Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond ...

Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond well to conventional medical treatments, often leading to significant ...

Background and objectives Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial ...

The anticonvulsant fosphenytoin is safe and effective in quickly decreasing pain from sudden attacks of acute trigeminal ...

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.

“If cleared by the FDA, we believe there is a potential to generate revenues from trigeminal nerve ablation in late ... trigeminal rhizotomy for the treatment of idiopathic trigeminal neuralgia ...

Bollywood star Salman Khan reveals his struggle with trigeminal neuralgia, a painful condition known as the ‘suicide disease’ ...

has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.

Technologies has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance.

submission to the FDA for trigeminal nerve ablation earlier than previous guidance. Dave Rosa, President and CEO of NeuroOne, stated: "Our OneRF ® ablation technology platform has already achieved ...